Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger

OBJECTIVE: To assess long‐term efficacy and safety of canakinumab and the response to vaccination in children ages ≤5 years with cryopyrin‐associated periodic syndrome (CAPS). METHODS: CAPS patients (ages ≤5 years) received 2 mg/kg canakinumab subcutaneously every 8 weeks; patients with neonatal‐ons...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheumatol
Main Authors: Brogan, Paul A., Hofer, Michael, Kuemmerle‐Deschner, Jasmin B., Koné‐Paut, Isabelle, Roesler, Joachim, Kallinich, Tilmann, Horneff, Gerd, Calvo Penadés, Inmaculada, Sevilla‐Perez, Belén, Goffin, Laurence, Lauwerys, Bernard R., Lachmann, Helen J., Uziel, Yosef, Wei, Xiaoling, Laxer, Ronald M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Pediatric Rheumatology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6899890/
https://ncbi.nlm.nih.gov/pubmed/31161734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.41004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados